Breaking News Instant updates and real-time market news.

MYL

Mylan

$36.97

5.61 (17.89%)

, TEVA

Teva

$23.04

0.2 (0.88%)

14:12
11/06/18
11/06
14:12
11/06/18
14:12

Wells upgrades Mylan to Outperform, sees more upside after today's rally

Wells Fargo analyst David Maris upgraded Mylan (MYL) to Outperform from Market Perform with an unchanged price target of $40. The stock in afternoon trading is up 18%, or $5.76, to $37.13. Mylan shares have underperformed the S&P 500 Index for the year-to-date, one year, two year, and five year periods and the shares trade at a discount to peer Teva (TEVA), Maris tells investors in a research note titled "Concerns Abound, but Valuation Attractive." The analyst, however, believes Mylan is positioned for near-term outperformance after the company maintained its 2018 earnings guidance. Maris previously saw risk to second half of 2018 estimates, but with today's Q3 results, he now believes the risk to the downside to Q4 estimates is lower than previously thought. Further, Mylan's statement that Q4 guidance can be achieved with or without new approvals "provides some upside to sentiment" if generic Advair or other approvals materialize, says the analyst. Maris thinks that even with today's rally, Mylan shares still have more than 10% additional upside potential to reach fair value.

MYL

Mylan

$36.97

5.61 (17.89%)

TEVA

Teva

$23.04

0.2 (0.88%)

  • 13

    Nov

MYL Mylan
$36.97

5.61 (17.89%)

11/06/18
BOFA
11/06/18
UPGRADE
BOFA
Buy
Mylan upgraded to Buy from Neutral at BofA/Merrill
11/06/18
11/06/18
UPGRADE
Target $42

Buy
Mylan upgraded to Buy after 'encouraging' Q3 report at BofA/Merrill
As previously reported, BofA Merrill Lynch analyst Jason Gerberry upgraded Mylan to Buy from Neutral, stating that its Q3 report provided encouraging updates regarding several of its business segments. He believes concerns around its broader portfolio look overdone as industry-level generic pricing is showing signs of stabilizing while the company also provided encouraging new product updates. Gerberry added that he views the 20% stock pullback as an attractive opportunity, but trimmed his price target on Mylan shares to $42 from $44 to reflect rebasing of EpiPen and generic Copaxone.
11/06/18
COWN
11/06/18
NO CHANGE
Target $31
COWN
Market Perform
Mylan business model looks broken, says Cowen
Cowen analyst Ken Cacciatore said Mylan's Q3 results confirm his thesis that the current business model looks broken. He said at some point a new product cycle needs to materialize, but in Mylan's case it hasn't happened in a material enough way. Cacciatore recommends avoiding the shares and he reiterated his Market Perform rating and $31 price target on Mylan.
11/06/18
WELS
11/06/18
UPGRADE
WELS
Outperform
Mylan upgraded to Outperform from Market Perform at Wells Fargo
TEVA Teva
$23.04

0.2 (0.88%)

10/18/18
WELS
10/18/18
NO CHANGE
WELS
Sandoz results 'potential warning signal' for generics, says Wells Fargo
Wells Fargo analyst David Maris views this morning's results from Novartis' (NVS) generic unit Sandoz as "another negative datapoint" for generic stocks, notably Teva (TEVA), Mylan (MYL) and Amneal Pharmaceuticals (AMNX). Novartis reported Sandoz net sales of $2.4B, down 4% on constant currency, and noted that sales were pressured by 8% pricing erosion in the quarter, Maris tells investors in a research note. Novartis also highlighted that U.S sales for Sandoz declined 17% due to "industry wide pricing pressure," Maris points out. The analyst views the quarter as a "potential warning signal" for the Q3 earnings season for companies with large U.S. commodity generic exposure. He maintains his caution on "generic industry margin risks."
11/01/18
WELS
11/01/18
NO CHANGE
WELS
Market Perform
Fear of missing out helping to push Teva, Mylan higher, says Wells Fargo
Wells Fargo analyst David Maris believes Teva (TEVA) shares are bouncing back to fair value from recent declines after the company reported Q3 earnings that beat his above consensus estimate and hosted a "surprisingly bullish" quarterly call. He also sees a spillover effect occurring with Mylan (MYL) as the generic sector's advance reinforces buyers' belief that the stocks are undervalued and investors' "fear of missing out" drives increased interest. While Maris acknowledges Ajovy, Austedo, cost cuts and tax management are doing well, he believes much of Teva's business continues to show significant challenges and keeps a Market Perform rating on the shares.
11/05/18
MSCO
11/05/18
UPGRADE
MSCO
Overweight
Teva upgraded to Overweight from Equal Weight at Morgan Stanley
11/05/18
11/05/18
UPGRADE
Target $27

Overweight
Teva upgraded to Overweight on turnaround potential at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Teva to Overweight from Equal Weight, citing three main reasons. First, he expects strong cost cutting to drive earnings that top consensus forecasts. Second, he believes new products should deliver sales that top consensus forecasts. Third, he believes the market will assign Teva shares a higher multiple as the company executes and drives net debt /EBITDA down. Risinger, who noted that his adjusted EBITDA estimates for 2019-2020 are 6%-8% above consensus, raised his price target on Teva shares to $27 from $20.

TODAY'S FREE FLY STORIES

STX

Seagate

$41.82

-0.23 (-0.55%)

12:55
11/20/18
11/20
12:55
11/20/18
12:55
Options
Seagate put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

TJX

TJX

$47.05

-1.92 (-3.92%)

12:52
11/20/18
11/20
12:52
11/20/18
12:52
Recommendations
TJX analyst commentary  »

TJX labor, transportation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ADI

Analog Devices

$89.07

3.52 (4.11%)

12:50
11/20/18
11/20
12:50
11/20/18
12:50
Upgrade
Analog Devices rating change  »

Analog Devices upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

EA

Electronic Arts

$82.95

-0.09 (-0.11%)

, MSFT

Microsoft

$102.65

-1.97 (-1.88%)

12:48
11/20/18
11/20
12:48
11/20/18
12:48
OnTheFly
Game On: Nintendo, Microsoft still committed to E3 as Sony plans to skip »

Welcome to "Game On," The…

EA

Electronic Arts

$82.95

-0.09 (-0.11%)

MSFT

Microsoft

$102.65

-1.97 (-1.88%)

SNE

Sony

$49.86

-1.12 (-2.20%)

NTDOY

Nintendo

$0.00

(0.00%)

ATVI

Activision Blizzard

$49.80

0.63 (1.28%)

T

AT&T

$29.79

-0.55 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 26

    Nov

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

12:40
11/20/18
11/20
12:40
11/20/18
12:40
Options
Bearish spread in Invesco Senior Loan Portfolio as shares set 52-week lows »

Bearish spread in Invesco…

12:40
11/20/18
11/20
12:40
11/20/18
12:40
General news
Treasury Action: yields are mixed along the curve »

Treasury Action: yields…

NOK

Nokia

$5.58

-0.145 (-2.53%)

12:35
11/20/18
11/20
12:35
11/20/18
12:35
Options
Nokia put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$125.44

-0.82 (-0.65%)

12:27
11/20/18
11/20
12:27
11/20/18
12:27
Hot Stocks
Motorola Solutions wins second patent infringement suit against Hytera Mobilfunk »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

CLF

Cleveland-Cliffs

$9.37

-0.6 (-6.02%)

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Options
Cleveland-Cliffs call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMAC

MMA Capital

$26.50

-0.2 (-0.75%)

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Conference/Events
MMA Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SANW

S&W Seed

$3.05

(0.00%)

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Conference/Events
S&W Seed to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

TGT

Target

$69.29

-7.84 (-10.16%)

, BBY

Best Buy

$64.05

1.86 (2.99%)

12:19
11/20/18
11/20
12:19
11/20/18
12:19
OnTheFly
Fly Intel: Wall Street's top stories at midday »

Stocks opened in negative…

TGT

Target

$69.29

-7.84 (-10.16%)

BBY

Best Buy

$64.05

1.86 (2.99%)

CPB

Campbell Soup

$40.60

2.13 (5.54%)

KLIC

Kulicke & Soffa

$22.18

2.28 (11.46%)

A

Agilent

$67.54

4.97 (7.94%)

LIVN

LivaNova

$102.03

-18.25 (-15.17%)

LB

L Brands

$30.14

-4.39 (-12.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 27

    Nov

  • 05

    Dec

  • 11

    Dec

  • 03

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/20/18
11/20
12:17
11/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/20/18
11/20
12:16
11/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$34.13

-1.16 (-3.29%)

12:10
11/20/18
11/20
12:10
11/20/18
12:10
Options
Puts lead calls 4:1 in Boston Scientific as implied volatilities lift »

Puts lead calls 4:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

12:10
11/20/18
11/20
12:10
11/20/18
12:10
General news
U.S. equities remain under pressure »

U.S. equities remain…

AMAT

Applied Materials

$36.27

1.85 (5.37%)

12:05
11/20/18
11/20
12:05
11/20/18
12:05
Options
Applied Materials call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:05
11/20/18
11/20
12:05
11/20/18
12:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

FB

Facebook

$133.04

1.42 (1.08%)

12:02
11/20/18
11/20
12:02
11/20/18
12:02
Hot Stocks
Facebook experiencing service issues »

Visiting Facebook.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EGRX

Eagle Pharmaceuticals

$48.01

-1.36 (-2.75%)

12:01
11/20/18
11/20
12:01
11/20/18
12:01
Conference/Events
Eagle Pharmaceuticals management to meet with RBC Capital »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 02

    Dec

SDRL

Seadrill

$14.63

-1.84 (-11.17%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Seadrill falls -11.2% »

Seadrill is down -11.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EROS

Eros International

$8.19

-1.16 (-12.41%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Eros International falls -12.4% »

Eros International is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 20

    Dec

LB

L Brands

$30.23

-4.3 (-12.45%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
L Brands falls -12.5% »

L Brands is down -12.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SCO

Scor ADR

$23.44

2.26 (10.67%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Scor ADR rises 10.9% »

Scor ADR is up 10.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.